Gao Ping, Zhang Weidong
Biostatistics, Innovatio Statistics, Inc, Bridgewater, New Jersey, USA.
Biostatistics, Sana Biotechnology, Inc. Cambridge, Massachusetts, USA.
J Biopharm Stat. 2025;35(4):500-514. doi: 10.1080/10543406.2024.2341673. Epub 2024 Apr 15.
Single-arm phase II trials are very common in oncology. A fixed sample trial may lack sufficient power if the true efficacy is less than the assumed one. Adaptive designs have been proposed in the literature. We propose a Simon's design based, adaptive sequential design. Simon's design is the most used fixed sample design for single-arm phase II oncology trials. A prominent feature of Simon's design is that it minimizes the sample size when there is no clinically meaningful efficacy. We identify Simon's trial as a special group sequential design. Established methods for sample size re-estimation (SSR) can be readily applied to Simon's design. Simulations show that simply adding SSR to Simon's design may still not provide desirable power. We propose some expansions to Simon's design. The expanded design with SSR can provide even more power.
单臂II期试验在肿瘤学中非常常见。如果真实疗效低于假设疗效,固定样本试验可能缺乏足够的检验效能。文献中已提出了适应性设计。我们提出一种基于西蒙设计的适应性序贯设计。西蒙设计是单臂II期肿瘤学试验中最常用的固定样本设计。西蒙设计的一个突出特点是,当不存在具有临床意义的疗效时,它能使样本量最小化。我们将西蒙试验确定为一种特殊的组序贯设计。既定的样本量重新估计(SSR)方法可很容易地应用于西蒙设计。模拟结果表明,简单地将SSR添加到西蒙设计中可能仍无法提供理想的检验效能。我们对西蒙设计提出了一些扩展。带有SSR的扩展设计可提供更高的检验效能。